Literature DB >> 11769769

Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme.

M R Al-Marri1.   

Abstract

OBJECTIVE: To determine the resistance pattern of Mycobacterium tuberculosis to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the State of Qatar after the implementation of DOTS and an expatriate screening programme on arrival.
METHOD: A state-wide, population-based, retrospective analysis of all cases of pulmonary tuberculosis with positive M. tuberculosis culture reported to the Division of Public Health TB Unit from January 1996 to December 1998. M. tuberculosis sensitivity testing was done by the Bactec method for isoniazid (INH), rifampicin (RMP), streptomycin (SM) and ethambutol (EMB). The results were interpreted as a daily change of the growth index of test vials (with drug) compared with controls.
RESULTS: There were 406 isolates with positive M. tuberculosis culture. Sixty-one (15%) were resistant to one or more of the four anti-tuberculosis drugs, of which 58 (95%) were from newly diagnosed cases (primary) and three (5%) were from previously treated cases (acquired). Primary resistance was as follows: any resistance 15%, INH 12.4%, RMP 2%, SM 5.2%, EMB 0.8% and multidrug resistance (MDR, resistance to INH and RMP at least) was found in 0.8%. Acquired resistance was as follows: any resistance 15%, INH 15%, RMP 5%, SM 5% and MDR 5%.
CONCLUSION: The prevalence of resistance to four anti-tuberculosis drugs is strikingly low due to the limited expatriate screening programme (chest radiography) and implementation of DOTS. The four-drug regimen is recommended for the initial phase of therapy until the results of sensitivity testing are known.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11769769

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

Review 1.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.

Authors:  Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen
Journal:  Lancet       Date:  2014-03-24       Impact factor: 79.321

Review 2.  Isoniazid-resistant tuberculosis in children: a systematic review.

Authors:  Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

3.  Drug susceptibility patterns of the Mycobacterium tuberculosis isolated from previously treated and new cases of pulmonary tuberculosis at German-Nepal tuberculosis project laboratory, Kathmandu, Nepal.

Authors:  Gobinda Thapa; Narayan Dutt Pant; Saroj Khatiwada; Binod Lekhak; Bhawana Shrestha
Journal:  Antimicrob Resist Infect Control       Date:  2016-08-31       Impact factor: 4.887

4.  Rodent-Related Zoonotic Pathogens at the Human-Animal-Environment Interface in Qatar: A Systematic Review and Meta-Analysis.

Authors:  Md Mazharul Islam; Elmoubashar Farag; Ahmad Mahmoudi; Mohammad Mahmudul Hassan; Ehsan Mostafavi; Khalid A Enan; Hamad Al-Romaihi; Muzzamil Atta; Abdel Rahim M El Hussein; Zilungile Mkhize-Kwitshana
Journal:  Int J Environ Res Public Health       Date:  2021-05-31       Impact factor: 3.390

5.  Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial.

Authors:  Amina Abdelaal; Hassan Abd El-Ghaffar; Mohammad Hosam Eldeen Zaghloul; Noha El Mashad; Ehab Badran; Amal Fathy
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-01-30       Impact factor: 3.944

6.  Health and well-being issues of Nepalese migrant workers in the Gulf Cooperation Council countries and Malaysia: a systematic review.

Authors:  Priyamvada Paudyal; Kavian Kulasabanathan; Jackie A Cassell; Anjum Memon; Padam Simkhada; Sharada Prasad Wasti
Journal:  BMJ Open       Date:  2020-10-26       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.